| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl Basic Information:
Pharmaceutical Grade Anesthetic – Ultra-Pure HCl Powder CAS 136-47-0: Tetracaine and Lidocaine
Lidocaine hydrochloride undergoes rapid metabolism by the liver, with both metabolites and unchanged drug excreted via the kidneys. The biotransformation process includes oxidative N-dealkylation, ring hydroxylation, amide linkage cleavage, and conjugation. N-dealkylation, the primary biotransformation pathway, produces monoethylglycinexylidide and glycinexylidide metabolites, which share similar but less potent pharmacological and toxicological properties with Lidocaine hydrochloride. About 90% of administered Lidocaine hydrochloride is excreted as various metabolites, while under 10% is excreted unchanged. The principal urinary metabolite is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl: A Premier Amide Local Anesthetic.
Increasing dosage correlates with heightened effects and toxicity. At sub-toxic plasma concentrations, it exhibits anti-convulsive properties.
Blood concentrations exceeding 5μg/ml-1 can induce convulsions.
){kind=link}